Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 961 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Sanofi submits MAA for Lyxumia

Lixisenatide, discovered by Zealand Pharma and licensed to Sanofi, is a once-daily GLP-1 receptor agonist for Type-2 diabetes . Sanofi is set to complete Phase III development of